IA
RNAC icon

IndexIQ Advisors’s Cartesian Therapeutics RNAC Stock Holding History

IndexIQ Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,111
Closed -$304K – 1473
2021
Q4 		$304K Sell
3,111
-201
-6% -$21.6K 0.01% 941
2021
Q3 		$413K Buy
3,312
+332
+11% +$40.1K 0.01% 782
2021
Q2 		$374K Sell
2,980
-356
-11% -$42.4K 0.01% 833
2021
Q1 		$453K Buy
+3,336
New +$414K 0.02% 402

Other funds holding RNAC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
N
NanoDimension Woodside, California $24.7M AUM 74.01% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

IndexIQ Advisors's RNAC Position: Q1 2022 in Review

IndexIQ Advisors sold out of Cartesian Therapeutics (RNAC) in Q1 2022, closing a stake of 3,111 shares — an estimated $304K sold.

IndexIQ Advisors first reported a position in RNAC in Q1 2021 and held it in 4 quarters. The position peaked at $453K in Q1 2021. 102 funds tracked by Wall St. Rank hold RNAC as of Q1 2022.

  • IndexIQ Advisors reported no remaining Cartesian Therapeutics position as of Q1 2022 after selling out during the quarter.
  • IndexIQ Advisors sold 3,111 Cartesian Therapeutics shares in Q1 2022, an estimated $304K.
  • IndexIQ Advisors first reported a position in Cartesian Therapeutics in Q1 2021 and held it in 4 quarters.
  • IndexIQ Advisors's Cartesian Therapeutics position peaked at $453K in Q1 2021.
  • 102 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.